Immunome, Inc. Current Liabilities
Immunome, Inc. (IMNM) had Current Liabilities of $35.71 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Liabilities, Current $35.71M.
- 2026-03-31: Liabilities, Current $27.41M.
- 2025-12-31: Liabilities, Current $44.99M.
- 2025-09-30: Liabilities, Current $31.45M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $35.71M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $27.41M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $44.99M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $31.45M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $22.88M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $30.80M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $54.31M 10-K · filed 2026-03-03 |
| 2024-09-30 | $39.53M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $39.90M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $30.77M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $21.83M 10-K · filed 2025-03-19 |
| 2023-09-30 | $23.11M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $26.39M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $24.83M 10-Q · filed 2023-05-05 |
| 2022-12-31 | $7.33M 10-K · filed 2024-03-28 |
| 2022-09-30 | $7.37M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $8.62M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $9.71M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $9.73M 10-K · filed 2023-03-16 |
| 2021-09-30 | $7.76M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $3.52M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $4.57M 10-Q · filed 2021-05-12 |
| 2020-12-31 | $3.04M 10-K · filed 2022-03-28 |
| 2020-09-30 | $5.41M 10-Q · filed 2020-11-16 |
| 2019-12-31 | $1.67M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |